http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 임세중(Se Jooung Rim) (검색결과 1 건)
- 무료
- 기관 내 무료
- 유료
-
비소세포 폐암에 대한 Cisplatinum , VP - 16 복합화학요법의 효과
김영준(Young Joon Kim),김주항(Joo Hang Kim),노재경(Jae Kyung Roh),정현철(Hyun Chul Chung),임세중(Se Jooung Rim),박용준(Yong Joon Park),장준(Joon Chang),김성규(Sung Kyu Kim),이원영(Won Young Lee),김병수(Byung Soo Kim) 대한내과학회 1989 대한내과학회지 Vol.36 No.5
N/A We initiated a phase II trial for non-small cell lung cancer (NSCLC). The therapy consisted of 2 cycles of cisplatin (80 mg/m2) and VP-16 (100 mg/m2) given every 3~4 weeks. After the initial 2 cycles of chemotherapy, the patients received radiotherapy consisting of 5,500~6,500 cGy/5.5~6.5 weeks, and then were on maintenace chemotherapy. The above trial was applied to 57 patients during the period of February 1986 to December 1987. The following results were obtained: 1) There were 3 patients (5.3%) with complete remission, 31 patients (54.4%) with partial remission, 13 patients (22.8%) with stable disease and 10 patients (17. 5%) with progressive disease. The overall response rate was 59.7% and the overall median duration of remission was 38.8 weeks (range, 10~55+weeks). 2) The overall median survival was 38 weeks (range, 13~91+weeks). A median survival of 57 weeks (range, 16~92+ weeks) for responders and 33 weeks (range, 13~55+weeks) for non-responders were achieved and there was a significant difference in duration of survival by response (p < 0.001). 3) The tumor response was significantly correlated with histology (squamous and large cell carcinoma greater than adenocarcinoma) and performance status (p<0.001, respectively), and the survival correlated with the extent of disease, performance status and histology. Combined radiotherapy achieved an increased response rate 4) The side effects were acceptable and reversible. We concluded that cisplation plus VP-16 chemotherapy is a useful regimen in the treatment of non-small cell lung cancer and a prospective randomized trial and long term follow-up is warranted.
연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
